BridgeMD
Anesthetic block of the erector muscles of the lumbar spine to relieve acute lumbar pain: pilot study
EU CTIS ID: 2024-511818-21-00
What this study is testing
The main objective is to validate the efficacy of anesthetic blocks of the erector spinae muscles, over the first 4 days, on the pain of muscle contractures, during a recent lumbago.
- Therapeutic confirmatory (Phase III)
A plain-language read of the study's public EU CTIS listing. The study team confirms the details.
Who can take part
You may be able to join if
- Male or female
- Age ≥ 18 years
- Patient with lumbago lasting less than 7 days despite analgesic / NSAID treatment.
- Patient with NS pain > 6
- Patient with Oswestry score ≥ 30
- Patient informed of the trial and having signed the informed consent form prior to any trial-specific procedure
You likely can't join if
- Presence of "red flag" (non-disc lumbago): o Motor deficit or signs of horsetail irritation o Inflammatory pain waking up in the 2nd half of the night o Tumoral context o Infectious context or fever o Altered general condition o Traumatic context o Osteoporotic context
- Pregnant or breastfeeding woman or woman refusing effective contraception
- Patient deprived of liberty or under legal protection (guardianship or curatorship)
- Patient participating in another clinical research protocol involving a drug or medical device
- Patient unable to follow the protocol, as judged by the investigator
- Patient refusing to participate in the study
See the full eligibility criteria
- Male or female
- Age ≥ 18 years
- Patient with lumbago lasting less than 7 days despite analgesic / NSAID treatment.
- Patient with NS pain > 6
- Patient with Oswestry score ≥ 30
- Patient informed of the trial and having signed the informed consent form prior to any trial-specific procedure
- Patient willing and able to undergo all planned examinations and procedures in compliance with the clinical trial protocol
- Patient affiliated to a social security or any health insurance
- Presence of "red flag" (non-disc lumbago): o Motor deficit or signs of horsetail irritation o Inflammatory pain waking up in the 2nd half of the night o Tumoral context o Infectious context or fever o Altered general condition o Traumatic context o Osteoporotic context
- Pregnant or breastfeeding woman or woman refusing effective contraception
- Patient deprived of liberty or under legal protection (guardianship or curatorship)
- Patient participating in another clinical research protocol involving a drug or medical device
- Patient unable to follow the protocol, as judged by the investigator
- Patient refusing to participate in the study
- Risk of infection
- Patient with poor local skin condition
- Patient on AVK or anti-Xa anticoagulation, or bleeding disorder (antiaggregants authorized)
- Patients with hypersensitivity to Ropivacaine or any of its excipients: Sodium chloride, hydrochloric acid sodium hydroxide
- Patient with sciatica
- Patient with chronic respiratory insufficiency
- Patient with cardiac rhythm disorders
- Pregnant or breastfeeding woman or woman refusing effective contraception
The study team makes the final eligibility decision.
Questions & answers
Do participants get paid in this trial?
This listing doesn't specify compensation. Many trials still reimburse travel or offer a stipend, so it's worth asking the study team when you connect.
Is it free to join, and do I need insurance?
Searching and applying through BridgeMD is free. In clinical trials the study-related treatment and visits are generally provided at no cost to you. You usually don't need insurance to take part - confirm specifics with the study team.
How long does this study last?
The listing doesn't state an exact length. The study team walks you through the schedule and number of visits before you decide to enroll.
Who can join this trial?
This study is enrolling all sexes, 65+ years, 18-64 years. The study team makes the final eligibility decision.
Explore other conditions
BridgeMD is an information and trial-matching tool - not medical advice, and not the study sponsor. Details come from EU CTIS; the study team decides eligibility.